A innovator in developing dynamically tumor-targeted nanopharmaceuticals.
Salgia. This randomized study should answer the question of whether CRLX101 can meaningfully impact an area of severely unmet medical require. .. Cerulean initiates CRLX101 Phase 2 research in extensive-stage small cell lung cancer Cerulean Pharma Inc., a innovator in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first individual provides been dosed in a randomized Stage 2 study of it is lead candidate, CRLX101, in sufferers with extensive-stage little cell lung cancers delicate to first-line platinum-centered chemotherapy. With the 150-patient randomized Phase 2 study in advanced non-small cell lung cancers expected to read aloud soon, Cerulean is broadening the CRLX101 chance in lung malignancy.Preeclampsia is a leading cause of preterm birth and maternal/fetal death, arising in 5-8 percent of pregnant mothers and characterized by high blood circulation pressure and proteins in the urine after week 20 of being pregnant. Related StoriesPresence of connexin proteins suppresses primary tumor growthStudy reveals system behind protein-related diseasesDiscovery can offer clues to how some infections control expression of genetic material The technology was discovered by Carmenta's co-founders, Dr. Atul Butte and Dr. Bruce Ling of Stanford University. Their study uncovered a novel combination of relevant clinically, proprietary proteins biomarkers in serum capable of identifying pregnant mothers with preeclampsia.